These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 24702982)

  • 21. [What management for the asymptomatic men carriers of BRCA1 or 2 mutation? Results of a survey in the French oncogenetic centers].
    Brachot-Simeonova I; Morin G; Gillaux C; Demeer B; Gondry J; Mathieu M; Fauvet R
    Bull Cancer; 2012 Apr; 99(4):417-23. PubMed ID: 22429936
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The frequency of germ-line mutations in the breast cancer predisposition genes BRCA1 and BRCA2 in familial prostate cancer. The Cancer Research Campaign/British Prostate Group United Kingdom Familial Prostate Cancer Study Collaborators.
    Gayther SA; de Foy KA; Harrington P; Pharoah P; Dunsmuir WD; Edwards SM; Gillett C; Ardern-Jones A; Dearnaley DP; Easton DF; Ford D; Shearer RJ; Kirby RS; Dowe AL; Kelly J; Stratton MR; Ponder BA; Barnes D; Eeles RA
    Cancer Res; 2000 Aug; 60(16):4513-8. PubMed ID: 10969800
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The rate of the founder Jewish mutations in BRCA1 and BRCA2 in prostate cancer patients in Israel.
    Vazina A; Baniel J; Yaacobi Y; Shtriker A; Engelstein D; Leibovitz I; Zehavi M; Sidi AA; Ramon Y; Tischler T; Livne PM; Friedman E
    Br J Cancer; 2000 Aug; 83(4):463-6. PubMed ID: 10945492
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Loss of heterozygosity at the BRCA2 locus detected by multiplex ligation-dependent probe amplification is common in prostate cancers from men with a germline BRCA2 mutation.
    Willems AJ; Dawson SJ; Samaratunga H; De Luca A; Antill YC; Hopper JL; Thorne HJ;
    Clin Cancer Res; 2008 May; 14(10):2953-61. PubMed ID: 18445692
    [TBL] [Abstract][Full Text] [Related]  

  • 25. BRCA1 and BRCA2 variants of uncertain significance. Part two: medical management.
    Miller-Samuel S; Rosenberg A; Berger A; Gomella L; Loren D; Morris GJ
    Semin Oncol; 2011 Oct; 38(5):605-11. PubMed ID: 21943665
    [No Abstract]   [Full Text] [Related]  

  • 26. Male BRCA mutation carriers: clinical characteristics and cancer spectrum.
    Ibrahim M; Yadav S; Ogunleye F; Zakalik D
    BMC Cancer; 2018 Feb; 18(1):179. PubMed ID: 29433453
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Patients with prostate cancer and BRCA2 mutations need urgent treatment.
    Torjesen I
    BMJ; 2013 Apr; 346():f2223. PubMed ID: 23571745
    [No Abstract]   [Full Text] [Related]  

  • 28. The Clinical Impact of BRCA2 Loss in Prostate Cancer.
    Bryant HE
    Eur Urol; 2016 Jun; 69(6):996-7. PubMed ID: 26708042
    [No Abstract]   [Full Text] [Related]  

  • 29. BRCA1 and BRCA2 have a limited role in familial prostate cancer.
    Sinclair CS; Berry R; Schaid D; Thibodeau SN; Couch FJ
    Cancer Res; 2000 Mar; 60(5):1371-5. PubMed ID: 10728701
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Studies of genes and cancer survival: pieces of the puzzle.
    Wacholder S; Loukissas JK; Hartge P
    J Natl Cancer Inst; 2007 Jun; 99(12):908-9. PubMed ID: 17565150
    [No Abstract]   [Full Text] [Related]  

  • 31. Improving Prostate Cancer Screening and Diagnosis: Health Policy and Biomarkers Beyond PSA.
    Patel HD; Chalfin HJ; Carter HB
    JAMA Oncol; 2016 Jul; 2(7):867-8. PubMed ID: 27031887
    [No Abstract]   [Full Text] [Related]  

  • 32. The role of genetic testing in prostate cancer screening, diagnosis, and treatment.
    de la Calle CM; Bhanji Y; Pavlovich CP; Isaacs WB
    Curr Opin Oncol; 2022 May; 34(3):212-218. PubMed ID: 35238838
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The role of the BRCA2 gene in susceptibility to prostate cancer revisited.
    Ostrander EA; Udler MS
    Cancer Epidemiol Biomarkers Prev; 2008 Aug; 17(8):1843-8. PubMed ID: 18708369
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High grade prostatic intraepithelial neoplasia does not display loss of heterozygosity at the mutation locus in BRCA2 mutation carriers with aggressive prostate cancer.
    Willems-Jones A; Kavanagh L; Clouston D; Bolton D; ; Fox S; Thorne H
    BJU Int; 2012 Dec; 110(11 Pt C):E1181-6. PubMed ID: 23035815
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Re: Prostate-specific antigen-based prostate cancer screening: Past and future.
    Birkeland S
    Int J Urol; 2016 Apr; 23(4):348. PubMed ID: 26839978
    [No Abstract]   [Full Text] [Related]  

  • 36. Editorial Comment to Prostate-specific antigen-based prostate cancer screening: Past and future.
    Sakamoto S
    Int J Urol; 2015 Jun; 22(6):532-3. PubMed ID: 25854711
    [No Abstract]   [Full Text] [Related]  

  • 37. [Germline testing for patients with metastatic and localized high-risk prostate cancer: Towards a widespread use?].
    Marchand-Créty C
    Bull Cancer; 2021 Nov; 108(11):994-998. PubMed ID: 34656301
    [No Abstract]   [Full Text] [Related]  

  • 38. BRCA2 mutation in a family with hereditary prostate cancer.
    Grönberg H; Ahman AK; Emanuelsson M; Bergh A; Damber JE; Borg A
    Genes Chromosomes Cancer; 2001 Mar; 30(3):299-301. PubMed ID: 11170288
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Prostate cancer and DNA repair genes].
    Penel N
    Bull Cancer; 2017 Nov; 104(11):958-961. PubMed ID: 29032803
    [No Abstract]   [Full Text] [Related]  

  • 40. Does inflammation reduce the risk of prostate cancer?
    Goldstraw MA; Kirby RS
    BJU Int; 2013 Oct; 112(6):710. PubMed ID: 24028760
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.